TY - JOUR
T1 - Endothelial to Mesenchymal Transition in Cardiovascular Disease
T2 - JACC State-of-the-Art Review
AU - Kovacic, Jason C.
AU - Dimmeler, Stefanie
AU - Harvey, Richard P.
AU - Finkel, Toren
AU - Aikawa, Elena
AU - Krenning, Guido
AU - Baker, Andrew H.
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/1/22
Y1 - 2019/1/22
N2 - Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological role of EndMT in CVDs (versus being a “bystander-phenomenon”), and a lack of robust human data corroborating the extent and causality of EndMT in adult CVDs. Here, we review this emerging but exciting field, and propose a framework for its systematic advancement at the molecular and translational levels.
AB - Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological role of EndMT in CVDs (versus being a “bystander-phenomenon”), and a lack of robust human data corroborating the extent and causality of EndMT in adult CVDs. Here, we review this emerging but exciting field, and propose a framework for its systematic advancement at the molecular and translational levels.
KW - cardiovascular
KW - EndMT
KW - endothelial to mesenchymal transition
UR - http://www.scopus.com/inward/record.url?scp=85059345045&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.09.089
DO - 10.1016/j.jacc.2018.09.089
M3 - Review article
C2 - 30654892
AN - SCOPUS:85059345045
SN - 0735-1097
VL - 73
SP - 190
EP - 209
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 2
ER -